Scientific Program

Sep. 3(Wed)

KSMO Initiatives for Cancer Care Inequity
Cancer Care Inequity with a focus on navigating access challenges pertaining to NGS, Precision Medicine, and therapeutics in the Asia Pacific region
Date & Time Sep. 3(Wed), 14:00-16:00 Venue Room D (Walker Hall 2)
Chair(s)
  • Changhoon Yoo (Asan Medical Center, Korea)
  • Omali Pitiyarachchi (University of New South Wales, Australia)
Session Details
  1. 1. Insights from the 2024 KSMO Young Oncologist Forum
    Omali Pitiyarachchi (University of New South Wales, Australia)
  2. 2. Advancing precision oncology in Japan: Evolving clinical trials and real-world practice
    Tatsunori Shimoi (Medical Oncology, National Cancer Center Hospital Tsukiji, Japan)
  3. 3. Current status of NGS reimbursement in Korea
    Hyehyun Jeong (Asan Medical Center, Korea)
  4. 4. Challenges and progress in cancer drug access in the Philippines
    Mary Antonette G. Ong-Chua (Antique Medical Center, Philippines)
  5. 5. The role of patient education in driving uptake of NGS testing from a Thailand Perspective
    Lucksamon Thamlikitkul (Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand)
  6. 6. Panel Discussion
    Joshua Tan (national cancer centre singapore, Singapore)
    Jordan Cohen (Calvary Mater Newcastle, Australia)
    Jiun-I Lai (Medical Oncology, Taipei Veterans General Hospital, Taiwan)
    Kyaw Zin Win (Mandalar Hospital, Mandalay, Myanmar)
    Zhuoran Yao (Cancer Center, West China Hospital, Sichuan University, China)
    Le Minh Hang (Can Tho Oncology Hospital, Vietnam)
    Javeria Haider (Atomic Energy Cancer Hospital NORI, Islamabad, Pakistan)
    Izzati Wan Maharuddin (Sarawak General Hospital, Kuching, Malaysia, Malaysia)
    Erty Sundarita (Sriwijaya University, Indonesia)
    Amit Kumar (Jay Prabha Medanta Superspeciality Hospital, India)
Education Session 1 (ES01)
Symptom management in advanced cancer: Innovations and best practices
Date & Time Sep. 3 (Wed), 16:10-17:30 Venue Room D (Walker Hall 2)
Chair(s)
  • Seong Hoon Shin (Kosin University Gospel Hospital, Korea)
  • Junghun Kang (Gyeongsang National University Hospital, Korea)
Session Details
  1. 1. New approach to manage toxicities of novel anticancer drugs
    Hee Jun Kim (Chung-Ang University College of Medicine, Korea)
  2. 2. Pharmacological innovations in symptom control
    Seyoung Seo (Asan Medical Center, Korea)
  3. 3. Advanced nursing approaches: Outpatient nurse-led telephone counseling for cancer symptom management
    Ji Youn Kim (Medical Oncology Clinical Nurse Specialist, Asan Medical Center, Korea)
  4. 4. Integrating clinical research and coordinated care for optimal symptom management
    Hee Kyung Ahn (Samsung Medical Center, Korea)

Sep. 4 (Thu)

ASCO/KSMO Joint Symposium 1 (JS01)
GI
Date & Time Sep. 4 (Thu), 08:40-10:10 Venue Room A (Vista Hall 1)
Chair(s)
  • Tae Won Kim (Asan Medical Center, Korea)
  • Elizabeth Mittendorf (Dana-Farber Cancer Institute, USA)
Session Details
  1. 1.Towards a deeper understanding of current therapies in gastric cancer – Lessons from translational research
    Samuel Klempner (Massachusetts General Hospital, USA)
  2. 2. Lessons learned from platform trials in GC: Optimizing the treatment strategy in GC
    Jeeyun Lee (Samsung Medical Center, Korea)
  3. 3.Landmark trials from keynote trials to destiny trials in GEC: What is next?
    Samuel Cytyrn (Memorial Sloan Kettering Cancer Center, USA)
  4. 4.Her2+ gastric cancer: Time to move forward
    Keun-Wook Lee (Seoul National University Bundang Hospital, Korea)
KCSG/KSMO Joint Symposium 2 (JS02)
Transforming oncology research: AI-powered clinical trials
Date & Time Sep. 4 (Thu), 08:40-10:10 Venue Room B (Vista Hall 3)
Chair(s)
  • Jin Seok Ahn (Samsung Medical Center, Korea)
  • Sook-ryun Park (Asan Medical Center, Korea)
Session Details
  1. 1.Clinical research and generative AI
    Hiromizu Takahashi (Juntendo University Urayasu Hospital, Japan)
  2. 2. AI-Driven patient recruitment and trial optimization
    Kenneth Kehl (Dana-Farber Cancer Institute, USA)
  3. 3.Clinical trial design and simulation with AI
    Sandip Pravin Patel (UC San Diego Moores Cancer Center, USA)
  4. 4.Regulatory and ethical considerations in AI-powered clinical trials
    Hannah Kim (Yonsei University College of Medicine, Korea)
Education Session 2 (ES02)
Tumor heterogeneity and single-cell analysis KOREAN
Date & Time Sep. 4 (Thu), 08:40-10:10 Venue Room C (Walker Hall 1)
Chair(s)
  • Sang Joon Shin (Yonsei University College of Medicine, Korea)
  • Kyoung Mee Kim (Samsung Medical Center, Korea)
Session Details
  1. 1. Tumor deconvolution-guided precision medicine in cancer
    Jinhyuk Bhin (Yonsei University College of Medicine, Korea)
  2. 2. Tracing cellular dynamics during intestinal tumorigenesis and metastasis
    Min Kyu Yum (KAIST, Korea)
  3. 3. Mapping and targeting tumor microenvironment in gastric cancer
    Hoon Hur (Ajou University School of Medicine, Korea)
  4. 4. Deciphering head and neck cancer microenvironment: Single-cell and spatial transcriptomics
    Yun Hak Kim (Pusan National University, Korea)
Scientific Symposium 1 (SS01)
Optimizing the transition to palliative care: Prognostic estimation and communication in oncology
Date & Time Sep. 4 (Thu), 08:40-10:10 Venue Room D (Walker Hall 2)
Chair(s)
  • Jin Hyuk Choi (Ajou University Hospital, Korea)
  • Eileen Poon (National Cancer Centre Singapore, Singapore)
Session Details
  1. 1. Prognostic estimation for optimal timing of palliative care referrals: From classic to novel
    Yusuke Hiratsuka (Takeda General Hospital, Japan)
  2. 2. Designing structured approaches for prognostic communication and goal of care discussions
    Young Kwang Chae (Northwestern University, USA)
  3. 3. Real world challenges in shared decision-making: Integrating information and values
    Beodeul Kang (CHA Bundang Medical Center, Korea)
  4. 4. Training oncologists in prognostic estimation and communication: Building essential skills for clinical practice
    Eun Mi Nam (Ewha Womans University Seoul Hospital, Korea)
Satellite Symposium 1 (SL01)
Amivantamab combination: Combined power to change the game in NSCLC
Date & Time Sep. 4 (Thu), 08:40-9:20 Venue Room E (Grand Hall 4)
Chair(s)
  • Young Joo Min (Ulsan University Hospital, Korea)
Session Details
  1. Combined power to change the game in EGFRm+ NSCLC: Amivintamab combination therapy
    Beung-Chul Ahn (National Cancer Center, Korea)
Satellite Symposium 2 (SL02)
Clinical values of Lorviqua(Lorlatinib) as a 1st line treatment for ALK positive mNSCLC patients
Date & Time Sep. 4 (Thu), 9:30-10:10 Venue Room E (Grand Hall 4)
Chair(s)
  • Dae-ho Lee (Asan Medical Center, Korea)
Session Details
  1. Redefining first-line standards: Lorlatinib in ALK+ mNSCLC
    Sun Min Lim(Yonsei University College of Medicine, Korea )
Plenary Lecture 1 (PL01)
Breaking new ground: Innovative cancer vaccine therapies
Date & Time Sep. 4 (Thu), 10:40-11:20 Venue Room A (Vista Hall 1)
Chair(s)
  • Joon Oh Park (Samsung Medical Center, Korea)
Session Details
  1. Breaking new ground: Innovative cancer vaccine therapies
    Patrick Ott (Dana-Farber Cancer Institute, USA)
Luncheon Symposium 1 (LS01)
Keytruda in HER2+ and HER2– gastric Cancer : Recent updates and real-world insights from KN811 & KN859
Date & Time Sep. 4 (Thu), 11:30-12:10 Venue Room A (Vista Hall 1)
Chair(s)
  • Min-hee Ryu (Asan Medical Center, Korea)
Session Details
  1. Keytruda in HER2+ and HER2– gastric Cancer : Recent updates and real-world insights from KN811 & KN859
    Seok Jae Huh (Dong-A University College of Medicine, Korea)
Luncheon Symposium 2 (LS02)
Confirmed efficacy data of Verzenio for high-risk EBC patients: MonarchE updates and 2yrs patient journey
Date & Time Sep. 4 (Thu), 11:30-12:10 Venue Room B (Vista Hall 3)
Chair(s)
  • Joohyuk Sohn (Yonsei Cancer Hospital, Korea)
Session Details
  1. Confirmed efficacy data of Verzenio for high-risk EBC patients : MonarchE updates and 2yrs patient journey
    Junghoon Shin (Samsung Medical Center, Korea)
Luncheon Symposium 3 (LS03)
FLAURA2: Advancing first-line therapy for patients with EGFRm NSCLC
Date & Time Sep. 4 (Thu), 11:30-12:10 Venue Room A (Vista Hall 1)
Chair(s)
  • Ki Hyeong Lee (Chungbuk National University Hospital, Korea)
Session Details
  1. FLAURA2: Advancing First-Line Therapy for Patients with EGFRm NSCLC
    Hye Ryun Kim (Yonsei Cancer Center, Korea)
Luncheon Symposium 4 (LS04)
Expanding the Horizon of HER2 Therapy: ADC Treatment for breast cancer patients across HER2 expression spectrum
Date & Time Sep. 4 (Thu), 11:30-12:10 Venue Room D (Walker Hall 2)
Chair(s)
  • Jee Hyun Kim (Seoul National University Bundang Hospital, Korea)
Session Details
  1. Expanding the horizon of HER2 therapy: ADC treatment for breast cancer patients across HER2 expression spectrum
    Heejung Chae (Seoul National University Bundang Hospital, Korea)
Luncheon Symposium 5 (LS05)
EGFRm+ NSCLC
Date & Time Sep. 4 (Thu), 11:30-12:10 Venue Room E (Grand Hall 4)
Chair(s)
  • Ji-Youn Han (National Cancer Center, Korea)
Session Details
  1. The LASER effect : Lazertinib's rise as a new SoC in EGFRm+ NSCLC 1L treatment
    Jinyong Kim (Samsung Medical Center, Korea)
Scientific Symposium 2 (SS02)
Revolutionizing GI cancer care with next-generation modalities
Date & Time Sep. 4 (Thu), 12:20-13:50 Venue Room A (Vista Hall 1)
Chair(s)
  • Sang-Cheol Lee (Soonchunhyang University Hospital, Korea)
  • Jin Li (Shanghai East Hospital, China)
Session Details
  1. 1. CLDN18.2: New target for gastric and pancreatic cancer
    Zev A. Weinberg (UCLA, USA)
  2. 2. Novel IO combinations for GI cancers: Beyond PD-1/PD-L1 and CTLA4
    Minsuk Kwon (Samsung Medical Center, Korea)
  3. 3. Emerging cell-based therapy for GI cancers
    Changsong Qi (Peking University Cancer Hospital and Institute, China)
  4. 4. Novel therapeutic vaccine for GI cancers
    Tetsuya Nakatsura (National Cancer Center, Japan)
Education Session 3 (ES03)
Cancer survivorship: Shifting paradigms in care KOREAN
Date & Time Sep. 4 (Thu), 12:20-13:50 Venue Room B (Vista Hall 3)
Chair(s)
  • Gyeong-Won Lee (Gyeongsang National University, Korea)
  • Soon Nam Lee (Ewha Womans University Mokdong Hospital, Korea)
Session Details
  1. 1. Surviving with emerging long-term toxicities
    Yun-Gyoo Lee (Kangbuk Samsung Hospital, Korea)
  2. 2. Genetic counseling for cancer survivors
    Ji Soo Park (Cancer Prevention Center, Yonsei Cancer Center, Korea)
  3. 3. Restoring emotional strength after cancer: Psychological interventions
    Seockhoon Chung (Asan Medical Center, Korea)
  4. 4. Empowered survivorship through digital health
    Juhee Cho (Samsung Comprehensive Cancer Center, Korea)
Scientific Symposium 3 (SS03)
How shall we treat RARE cancer in the era of precision medicine : Progress and challenges ahead
Date & Time Sep. 4 (Thu), 12:20-13:50 Venue Room C (Walker Hall 1)
Chair(s)
  • Eun Mi Nam (Ewha Womans University Seoul Hospital, Korea)
  • Jen-Shi Chen (Linkou Chang Gung Memorial Hospital, Taiwan)
Session Details
  1. 1. How can we facilitate personalized trial for rare cancers: KCSG experience
    Bhumsuk Keam (Seoul National University Hospital, Korea)
  2. 2. Role of (pre)clinical trials in rare cancer: Focusing on adenoid cystic carcinoma
    Hyunseok Kang (UCSF, USA)
  3. 3. Tracing molecular evolution of glioblastoma: Will it make some changes?
    Michael Lim (Standford University, USA)
  4. 4. Integration of immune-oncology in treatment of GBM: Recent updates and future direction
    Jong Bae Park (National Cancer Center, Korea)
KOSRO/KSMO Joint Symposium 3 (JS03)
Optimization of neoadjuvant/adjuvant treatment
Date & Time Sep. 4 (Thu), 12:20-13:50 Venue Room D (Walker Hall 2)
Chair(s)
  • Hak Jae Kim (Seoul National University Hospital, Korea)
  • TBD
Session Details
  1. 1. Optimization of adjuvant radiotherapy in breast cancer
    Bruno Meduri (Azienda Provinciale per i Servizi Sanitari (APSS), Italy)
  2. 2. Rectal cancer TNT
    Deborah Schrag (Memorial Sloan Kettering Cancer Center, USA)
  3. 3. NSCLC neoadjuvant regimen
    Jang Ho Cho (Gachon University Gil Medical Center, Korea)
  4. 4. Radiotherapy for sacroma: Overcoming traditional perceptions and exploring future directions
    Jeong Il Yu (Samsung Medical Center, Korea)
Satellite Symposium 3 (SL03)
Pembrolizumab, rewriting the treatment paradigm in 1L endometrial cancer
Date & Time Sep. 4 (Thu), 12:20-13:00 Venue Room E (Grand Hall 4)
Chair(s)
  • Gun Min Kim (Yonsei Cancer Hospital, Korea)
Session Details
  1. Pembrolizumab, rewriting the treatment paradigm in 1L endometrial cancer
    In Hee Lee (Kyungpook National University Chilgok Hospital, Korea)
Satellite Symposium 4 (SL04)
Bridging VISION to reality: Clinical insights into PSMA RLT adoption
Date & Time Sep. 4 (Thu), 13:10-13:50 Venue Room E (Grand Hall 4)
Chair(s)
  • Keon-Uk Park (Keimyung University Dongsan medical Center, Korea)
Session Details
  1. Bridging VISION to reality: Clinical insights into PSMA RLT adoption
    Inkeun Park (Asan Medical Center, Korea)
ESMO/KSMO Joint Symposium 4 (JS04)
ESMO guideline and the implementation in Asian Pacific region
Date & Time Sep. 4 (Thu), 14:00-15:30 Venue Room A (Vista Hall 1)
Chair(s)
  • Myung Ah Lee (The Catholic University of Korea Seoul St. Mary’s Hospital, Korea)
  • Fabrice André (Gustave Roussy, Villejuif, France)
Session Details
  1. 1. Case presentation
    Kyung-Hun Lee (Seoul National University Hospital, Korea)
  2. 2. Critical analysis and presentation of the ESMO Guideline early-onset breast cancer, with MCBS and ESCAT
    Fabrice André (Gustave Roussy, Villejuif, France)
  3. 3. Asian perspectives on genetics, practice, and applicability of ESMO guideline in early-onset breast cancer
    Jee Hyun Kim (Seoul National University Bundang Hospital, Korea)
  4. 4. Case presentation
    Inkeun Park (Asan Medical Center, Korea)
  5. 5. Critical analysis and presentation of the ESMO Guideline - Kidney cancer, with ESMO-MCBS and ESCAT
    Matthew Young (Barts Cancer Institute, Queen Mary University of London, UK)
  6. 6. "Asian” perspectives on genetics, practice and applicability: Urologic oncologist's perspective
    Jae Lyun Lee (Asan Medical Center, Korea)
KSSO/KSMO Joint Symposium 5 (JS05)
Omit surgery in GI cancer treatment
Date & Time Sep. 4 (Thu), 14:00-15:30 Venue Room B (Vista Hall 3)
Chair(s)
  • Joong Bae Ahn (Yonsei University College of Medicine, Korea)
  • Naru Kim (Ewha Womans University College of Medicine, Korea)
Session Details
  1. 1. Omitting surgery in pancreatic cancer: Can systemic therapy alone replace resection?
    Kosuke Kobayashi (Cancer Institute Hospital, Japan)
  2. 2. Omit surgery in rectal cancer: Is watch-and-wait a viable long-term strategy?
    Minsu Kang (Seoul National University Bundang Hospital, Korea)
  3. 3. Omit surgery in gastric cancer: When can we rely on non-surgical therapy alone?
    Jaemin Jo (Jeju National University Hospital, Korea)
  4. 4. Local therapies vs surgery in hepatocellular carcinoma: Is resection always necessary?
    Kenneth Chok (The Chinese University of Hong Kong, Hong Kong)
Education Session 4 (ES04)
Toxicity management in Antibody-Drug Conjugates (ADCs) KOREAN
Date & Time Sep. 4 (Thu), 14:00-15:30 Venue Room C (Walker Hall 1)
Chair(s)
  • Jong Gwang Kim (Kyungpook National University Chilgok Hospital, Korea)
  • Kyoung Eun Lee (Ewha Women's University Hospital, Korea)
Session Details
  1. 1. Structural and functional drivers of ADC toxicity
    In Hae Park (Korea University Guro Hospital, Korea)
  2. 2. Overview of toxicities of ADCs (including hematologic toxicities)
    Han Jo Kim (Soonchunhyang University Cheonan Hospital, Korea)
  3. 3. Pulmonary toxicities from ADCs
    Jimyung Park (Seoul National University Hospital, Korea)
  4. 4. Ocular toxicities from ADCs
    Chang Ho Yoon (Seoul National University Hospital, Korea)
Scientific Symposium 4 (SS04)
Current trends and future perspectives in GU oncology
Date & Time Sep. 4 (Thu), 14:00-15:30 Venue Room D (Walker Hall 2)
Chair(s)
  • Hyun Woo Lee (Ajou University Hospital, Korea)
  • James Lynam (Calvary Mater Hospital, Australia)
Session Details
  1. 1. Mechanism-based treatment strategies in RCC
    Ramaprasad Srinivasan (National Cancer Institute, USA)
  2. 2. Biomarkers in RCC: Current status and future direction
    David Braun (Yale School of Medicine, USA)
  3. 3. Antibody-drug conjugate in advanced urothelial carcinoma: Established & emerging drugs
    Hyeon-Su Im (Ulsan University Hospital, Korea)
  4. 4. How can we integrate PARP inhibitors in treatment of prostate cancer?
    Hyunho Kim (The Catholic University of Korea St. Vincent's Hospital, Korea)
Satellite Symposium 5 (SL05)
Advances and innovations in ES-SCLC treatment
Date & Time Sep. 4 (Thu), 14:00-14:40 Venue Room E (Grand Hall 4)
Chair(s)
  • Jong Mu Sun (Samsung Medical Center, Korea)
Session Details
  1. Targeting DLL3 with BiTE therapy: A new paradigm in SCLC treatment
    Jeonghwan Youk(Seoul National University Hospital, Korea)
Satellite Symposium 6 (SL06)
Optimizing HCC treatment sequence
Date & Time Sep. 4 (Thu), 14:50-15:30 Venue Room E (Grand Hall 4)
Chair(s)
  • Hong Jae Chon (Cha Bundang Medical Center, Korea)
Session Details
  1. Optimizing HCC patient outcomes across first-line IO based therapies and second-line real world practice management
    Changhoon Yoo (Asan Medical Center, Korea)
Plenary Lecture 2 (PL02)
Cancer cachexia: Transition from science to practice
Date & Time Sep. 4 (Thu), 15:40-16:20 Venue Room A (Vista Hall 1)
Chair(s)
  • Kyung Hee Lee (Yeungnam University, Korea)
Session Details
  1. Cancer cachexia: Transition from science to practice
    Jeffrey Crawford (Duke Cancer Center, USA)
Scientific Symposium 5 (SS05)
Current Insights and future directions of MBC treatment
Date & Time Sep. 4 (Thu), 16:20-17:50 Venue Room A (Vista Hall 1)
Chair(s)
  • Seock-Ah Im (Seoul National University Hospital, Korea)
  • Janice Tsang (The Hong Kong Cancer Therapy Society, Hong Kong)
Session Details
  1. 1. Targeting PTEN/PI3K/AKT pathway: Roles and limitations
    Carlos Arteaga (UT Southwestern Harold C. Simmons Cancer Center, USA)
  2. 2. Optimizing anti-Her2 treatment in the era of ADCs
    Jieun Park (Jeju National University Hospital, Korea)
  3. 3. Cutting-edge advances in TNBC: Beyond immunotherapy
    Kyong Hwa Park (Korea University Anam Hospital, Korea)
  4. 4. Managing oligometastasis- Is it curable?
    Gun Min Kim (Yonsei University College of Medicine, Korea)
Oral Presentation 1 (OP01)
TBD
Date & Time Sep. 4 (Thu), 16:20-17:20 Venue Room B (Vista Hall 3)
Chair(s)
  • Se Hyun Kim (Seoul National University Bundang Hospital, Korea)
  • Yeesoo Chae (Kyungpook National University Medical Center, Korea)
Session Details
  1. 1. Demographic and Clinical Predictors of Survival Among Patients with Second Malignant Neoplasms Following Primary Tongue Cancer: A Population-Based Study
    Ahmed Elkoumi (Faculty of Oral and Dental Medicine, Egyptian Russian University, Egypt)
  2. 2. Clinical Effect of Bisphosphonate in Patients with Hormone Receptor-Positive Early Breast Cancer: A Nationwide Real-World Data Analysis
    WonSeok Choi (Korea University Guro Hospital, Korea)
  3. 3. Association between genomic features and radiation response in metastatic breast cancer patients undergoing palliative radiotherapy
    Hyeon Seok Choi (Seoul National University College of Medicine, Korea)
  4. 4. The Impact of Brain MRI Surveillance on Survival Outcomes in Initially CNS Metastasis-free Non-Small Cell Lung Cancer
    Seong-Eun Kim (Asan Medical Center, Korea)
  5. 5. Durvalumab-based treatment for recurrent or metastatic pulmonary sarcomatoid carcinoma: pooled analysis of two KCSG trials
    Dong Hyun Kim (Seoul National University Hospital, Korea)
  6. 6. Evaluating Immunotherapy Outcomes in Elderly Patients with Extensive-Stage Small-Cell Lung Cancer (KCSG LU23-15)
    Yun-Gyoo Lee (Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Korea)
Scientific Symposium 6 (SS06)
Clinical promise of ctDNA-based MRD testing in solid tumors
Date & Time Sep. 4 (Thu), 16:20-17:50 Venue Room C (Walker Hall 1)
Chair(s)
  • Tae-You Kim (Seoul National University Hospital, Korea)
  • TBD
Session Details
  1. 1. ctDNA MRD for solid tumors: Translating clinical evidence into practice
    Yongjun Cha (IMB Dx, Korea)
  2. 2. ctDNA MRD for solid tumors: Overcoming technical challenges for broader clinical implementation
    Aadel Chaudhuri (Mayo Clinic, USA)
  3. 3. Striving for a quantum leap on Molecular Residual Disease (MRD) clinical development: Insights from CIRCULATE-JAPAN & SCRUM- MONSTAR
    Takayuki Yoshino (National Cancer Center Hospital East, Japan)
  4. 4. Leveraging ctDNA MRD in clinical trials and drug development: Opportunities and outlook
    Aparna Parikh (Massachusetts General Hospital, USA)
KSR/KSMO Joint Symposium 6 (JS06)
Radiomics Revolution: AI and imaging in cancer care
Date & Time Sep. 4 (Thu), 16:20-17:50 Venue Room D (Walker Hall 2)
Chair(s)
  • Ho Sung Kim (Asan Medical Center, Korea)
  • Joung Soon Jang (Chung-ang University Hospital, Korea)
Session Details
  1. 1. The prognostic role of CT-determined sarcopenia in cancer treatment outcomes
    Young Saing Kim (Gachon University Gil Medical Center, Korea)
  2. 2. Using CT-derived body composition indices to predict CDK4/6 inhibitor response in breast cancer patients
    Min Hwan Kim (Yonsei Cancer Center, Korea)
  3. 3. Radiomics and AI in lung cancer assessment
    Guillaume Chassagnon (Université Paris Cité, France)
  4. 4. Radiomics and AI in neuro-oncology
    Sung Soo Ahn (Yonsei University College of Medicine, Korea)
Satellite Symposium 7 (SL07)
Optimizing outcomes with Cabometyx in patients with mRCC considering latest changes in treatment sequence
Date & Time Sep. 4 (Thu), 16:20-17:00 Venue Room E (Grand Hall 4)
Chair(s)
  • Woo Kyun Bae (Chonnam National University Hwasun Hospital, Korea)
Session Details
  1. Optimizing outcomes with Cabometyx in patients with mRCC considering latest changes in treatment sequence
    Chang Gon Kim (Yonsei Cancer Center, Korea)
Satellite Symposium 8 (SL08)
Later-line treatment for mCRC patients (Draft)
Date & Time Sep. 4 (Thu), 17:10-17:50 Venue Room E (Grand Hall 4)
Chair(s)
  • Seung Tae Kim (Samsung Medical Center, Korea)
Session Details
  1. Treatment for metastatic colorectal cancer : Focused on FTD/TPI (Draft)
    Jwa Hoon Kim (Korea University Anam Hospital, Korea)

Sep. 5 (Fri)

JSMO/KSMO Joint Symposium 7 (JS07)
The new standard therapy in solid tumors : The combination of immunotherapies
Date & Time Sep. 5 (Fri), 08:40-10:10 Venue Room A (Vista Hall 1)
Chair(s)
  • Baek-Yeol Ryoo (Asan Medical Center, Korea)
  • Hironobu Minami (Kobe University, Japan)
Session Details
  1. 1. Frontline therapy in MSI-H metastatic colorectal cancer
    Junho Lee (Kyung Hee University Hospital, Korea)
  2. 2. Frontline therapy in metastatic hepatocellular carcinoma
    Hong sik Kim (Chungbuk National University Hospital, Korea)
  3. 3. Adjuvant and neoadjuvant therapy for melanoma in East Asia
    Kenjiro Namikawa (National Cancer Center Hospital, Tokyo, Japan)
  4. 4. Preoperative and frontline therapy in breast cancer (TNBC)
    Kenji Tamura (Shimane University Hospital, Japan)
Education Session 5 (ES05)
Advance of technology - Artificial intelligence in oncology KOREAN
Date & Time Sep. 5 (Fri), 08:40-10:10 Venue Room B (Vista Hall 3)
Chair(s)
  • Sang-Hee Cho (Chonnam National University Hwasun Hospital, Korea)
Session Details
  1. 1. Introduction: Artificial intelligence in oncology
    Chanyoung Ock (Lunit, Korea)
  2. 2. Clinical application of radiology-based AI model for breast cancer: Current and future
    Eunkyung Kim (Yonsei University College of Medicine, Korea)
  3. 3. Clinical application of pathology-based AI model: Current and future
    Yoon Jin Cha (Gangnam Severance Hospital, Korea)
  4. 4. LLM based medical research
    Jeong Moo Lee (Seoul National University Hospital, Korea)
Scientific Symposium 7 (SS07)
Novel opportunities to target cancer: Emerging strategies in molecular oncology
Date & Time Sep. 5 (Fri), 08:40-10:10 Venue Room C (Walker Hall 1)
Chair(s)
  • Do-Youn Oh (Seoul National University Hospital, Korea)
  • TBD
Session Details
  1. 1. Exploring the cell death phenotypic landscape for cancer
    Scott J. Dixon (Stanford University, USA)
  2. 2. Repurposing cardiac drugs beta-blockers for cancer treatment
    Erica Sloan (Monash University, Australia)
  3. 3. Targeting metastatic cancer via synthetic lethality
    Mi-Young Kim (KAIST, Korea)
  4. 4. Application of space medicine for lung cancer
    Hargsoon Yoon (Norfolk State University, USA)
KSP/KSMO Joint Symposium 8 (JS08)
Biomarker for ADC
Date & Time Sep. 5 (Fri), 08:40-10:10 Venue Room D (Walker Hall 2)
Chair(s)
  • Sang Cheul Oh (Korea University Guro Hospital, Korea)
  • Gian Franco Zannoni (Università Cattolica del Sacro Cuore, Italy)
Session Details
  1. 1. Companion diagnostics update and future strategy for oncology
    Jan Trøst Jørgensen (Dx-Rx Institute, Fredensborg, Denmark)
  2. 2. Biomakrer development for ADC
    Yoon-La Choi (Samsung Medical Center, Korea)
  3. 3. Recent optimization of ADC CDx : FOLR1 IHC
    Gian Franco Zannoni(Università Cattolica del Sacro Cuore, Italy)
  4. 4. Application of AI for biomarker interpretation
    Tae-Yeong Kwak (Deep Bio Inc., Korea)
Satellite Symposium 9 (SL09)
Paradigm shift in the treatment of mCRC: Unveiling the potential of FRUZAQLA
Date & Time Sep. 5 (Fri), 08:40-9:20 Venue Room E (Grand Hall 4)
Chair(s)
  • Seung Hoon Beom (Yonsei Cancer Hospital, Korea)
Session Details
  1. Paradigm shift in the treatment of mCRC: Unveiling the potential of FRUZAQLA
    Takayuki Yoshino (National Cancer Center Hospital East, Japan)
Satellite Symposium 10 (SL10)
Recent clinical data and real-world case updates on Opdivo in gastric cancer first-line treatment
Date & Time Sep. 5 (Fri), 09:30-10:10 Venue Room E (Grand Hall 4)
Chair(s)
  • Keun-Wook Lee (Seoul National University Bundang Hospital, Korea)
Session Details
  1. Recent clinical data and real-world case updates on Opdivo in gastric cancer first-line treatment
    Jaewon Hyung (Asan Medical Center, Korea)
Plenary Lecture 3 (PL03)
Advances in chemotherapy for gastric cancer- Future perspectives
Date & Time Sep. 5 (Fri), 10:30-11:10 Venue Room A (Vista Hall 1)
Chair(s)
  • Sun Young Rha (Yonsei University College of Medicine, Korea)
Session Details
  1. Advances in chemotherapy for gastric cancer- Future perspectives
    Kohei Shitara (National Cancer Center Hospital East, Japan)
Luncheon Symposium 6 (LS06)
Innovative SCLC treatment approaches
Date & Time Sep. 5 (Fri), 11:30-12:10 Venue Room A (Vista Hall 1)
Chair(s)
  • Young-Woong Won (Hanyang University Guri Hospital, Korea)
Session Details
  1. Advancing SCLC management with Lurbinectedin clinical experience and IMforte study innovations
    TBD
Luncheon Symposium 7 (LS07)
From mTNBC to HR+/HER2- mBC: Sacituzumab Govetican leads the way with proven survival benefit
Date & Time Sep. 5 (Fri), 11:30-12:10 Venue Room B (Vista Hall 3)
Chair(s)
  • Kyong Hwa Park (Korea University ANAM Hospital, Korea)
Session Details
  1. From mTNBC to HR+/HER2- mBC: Sacituzumab Govetican leads the way with proven survival benefit
    Dae-Won Lee (Seoul National University Hospital, Korea)
Luncheon Symposium 8 (LS08)
Game changer in GC treatment: New hope for CLDN18.2 positive patients
Date & Time Sep. 5 (Fri), 11:30-12:10 Venue Room C (Walker Hall 1)
Chair(s)
  • TBD
Session Details
  1. The breakthrough in gastric cancer: VYLOY new hope for CLDN18.2 positive patients (TBD)
    Choong-kun Lee (Yonsei Cancer Center, Korea)
Luncheon Symposium 9 (LS09)
Treatment unmet needs in HR+/HER2- early breast cancer & recent clinical evidence of Ribociclib
Date & Time Sep. 5 (Fri), 11:30-12:10 Venue Room D (Walker Hall 2)
Chair(s)
  • Yeon Hee Park (Samsung Medical Center, Korea)
Session Details
  1. Ribociclib: Paving the future of early breast cancer treatment (TBD)
    Jee Hyun Kim (Seoul National University Bundang Hospital, Korea)
Luncheon Symposium 10 (LS10)
Personalized treatment to maximize outcomes for CCA : Focused on Ivosidenib
Date & Time Sep. 5 (Fri), 11:30-12:10 Venue Room E (Grand Hall 4)
Chair(s)
  • Hei Cheul Jeung (Gangnam Severance Cancer Hospital, Korea)
Session Details
  1. Exploring long-term treatment outcomes with Ivosidenib in CCA (TBD)
    Beodeul Kang (CHA Bundang Medical Center, Korea)
ASCO/KSMO Joint Symposium 9 (JS09)
TBD
Date & Time Sep. 5 (Fri), 12:20-13:50 Venue Room A (Vista Hall 1)
Chair(s)
  • Joon Oh Park (Samsung Medical Center, Korea)
  • Elizabeth Mittendorf (Dana-Farber Cancer Institute, USA)
Session Details
  1. 1. NGS: Should all metastatic cancer patients receive NGS as part of practice: US perspectives
    Steve Maron (Memorial Sloan Kettering Cancer Center, USA)
  2. 2. NGS: Should all metastatic cancer patients receive NGS as part of practice: Korean perspectives
    Sung Hee Lim (Samsung Medical Center, Korea)
  3. 3. NGS benefits biliary tract cancer patients
    Haley Ellis (Massachusetts General Hospital, USA)
  4. 4. NGS benefits rare cancer patients
    Hyo song Kim (Yonsei University College of Medicine, Korea)
Oral Presentation 2 (OP02)
TBD
Date & Time Sep. 5 (Fri), 12:20-13:20 Venue Room B (Vista Hall 3)
Chair(s)
  • Tae-Yong Kim (Seoul National University Hospital, Korea)
  • TBD
Session Details
  1. 1. A phase II clinical trial of Bevacizumab plus eRlotinIb in patients with advanced cancer having genetic alterations in the Krebs cycle (BRISK): KCSG AL22-16
    Hyehyun Jung (CHA University, Korea)
  2. 2. Liposomal Irinotecan with Fluorouracil and Leucovorin as Salvage Treatment for Advanced Biliary Tract Cancer Refractory to Gemcitabine and Cisplatin
    Hyunho Kim (St. Vincents Hospital, College of Medicine, The Catholic University of Korea, Korea)
  3. 3. Referral Timing for Palliative Care Consultation and Its Associations with End-of-Life Outcomes in Patients with Cancer
    Jung Sun Kim (CHA University Bundang Medical Center, Korea)
  4. 4. Prognostic Significance of PTEN Gene Mutations and Loss of Expression in Colorectal Cancer
    Asgar Ali (All India Institute of Medical Sciences Patna, India)
  5. 5. Prognostic impacts of FGFR2b and genetic variation in patients with poorly cohesive cells gastric cancer
    Yunji Lee (Kyungpook National University Chilgok Hospitals, Korea)
  6. 6. Favorable Outcomes of EBV-Associated Gastric Cancer Treated with First-Line Immunotherapy Plus Chemotherapy: A Multicenter Real-World Study
    In-Ho Kim (Seoul St. Mary's Hospital, The Catholic University of Korea, Korea)
Multi-Disciplinary Case Discussion (MDCD)
Personalized treatment strategies for oligometastatic patients in the new era of cancer therapeutics KOREAN
Date & Time Sep. 5 (Fri), 12:20-13:50 Venue Room C (Walker Hall 1)
Chair(s)
  • Kyubo Kim (Seoul National University Bundang Hospital, Korea)
  • Sung Yong Oh (Donga University Hospital, Korea)
Session Details
  1. 1. LCT and the possibility of cure in oligometastatic NSCLC: For whom, and to what extent?
    Chai Hong Rim (Korea University College of Medicine, Korea)
  2. 2. Integrating local and systemic therapies for oligometastatic patients in the new era of novel cancer treatments
    In Hee Lee (Kyungpook National University Chilgok Hospital, Korea)
  3. 3. Biomarkers in oligometastasis: Current insights and future directions
    Dae-Won Lee (Seoul National University College of Medicine, Korea)
  4. 4. Spine SBRT
    Hwa Kyung Byun (Yongin Severance Hospital, Korea)
Scientific Symposium 8 (SS08)
Combinatory strategy to enhance immune checkpoint response
Date & Time Sep. 5 (Fri), 12:20-13:50 Venue Room D (Walker Hall 2)
Chair(s)
  • Tae Min Kim (Seoul National University Hospital, Korea)
Session Details
  1. 1. Optimal immunotherapy combination strategies for hepatobiliary cancer
    Changhoon Yoo (Asan Medical Center, Korea)
  2. 2. Recent advances of bispecific antibody for cancer immunotherapy
    Sangmi Lee (ABL Bio., Korea)
  3. 3. Novel ADCs and immune modulating agents to overcome immunotherapy resistance
    Toshio Shimizu (Kansai Medical University Hospital, Osaka, Japan)
  4. 4. Inducing anti-tumor immune response by radiation therapy
    Kyung Hwan Kim (Yonsei Cancer Center, Korea)
Satellite Symposium 11 (SL11)
New horizons in nausea and vomiting: Rethinking MEC strategies
Date & Time Sep. 5 (Fri), 12:20-13:00 Venue Room E (Grand Hall 4)
Chair(s)
  • Jung Hye Kwon (Chung-Ang University Gwangmyeong Hospital, Korea)
Session Details
  1. New horizons in nausea and vomiting: Rethinking MEC strategies
    Karin Jordan (Klinikum Ernst von Bergmann Potsdam, Germany)
Satellite Symposium 12 (SL12)
From data to practice: Optimizing ADC + IO in advanced UC (TBD)
Date & Time Sep. 5 (Fri), 13:10-13:50 Venue Room E (Grand Hall 4)
Chair(s)
  • Hyo-Jin Lee (Chungnam National University Hospital, Korea)
Session Details
  1. From Data to Practice: Optimizing ADC + IO in advanced UC (TBD)
    Minsuk Kwon (Samsung Medical Center, Korea)
Plenary Lecture 4 (PL04)
Biomarkers to predict efficacy and toxicity of antibody drug conjugates in breast cancer
Date & Time Sep. 5 (Fri), 14:00-14:40 Venue Room A (Vista Hall 1)
Chair(s)
  • Sung-bae Kim (Asan Medical Center, Korea)
Session Details
  1. Biomarkers to predict efficacy and toxicity of antibody drug conjugates in breast cancer
    Giuseppe Curigliano (European Institute of Oncology, IRCCS and Università degli Studi di Milano, Italy)
ESMO/KSMO Joint Symposium 10 (JS10)
How to streamline initiatives for optimising oncology practice
Date & Time Sep. 5 (Fri), 14:50-16:20 Venue Room A (Vista Hall 1)
Chair(s)
  • Dong-Wan Kim (Seoul National University Hospital, Korea)
  • Fabrice André (Gustave Roussy, Villejuif, France)
Session Details
  1. 1. ESMO ETAC-Tumour agnostic oncology: Drug development trends and mindsets
    Fernanda Mosele (Gustave Roussy, France)
  2. 2. “Asian” perspectives on drug development challenges and breakthroughs
    Sang Joon Shin (Yonsei Cancer Center, Korea)
  3. 3. Generative AI for treatment decisions
    Titus Brinker (German Cancer Research Center, Germany)
  4. 4. Generative AI and clinical decision support system utility in the hospital
    Wonchul Cha (Samsung Medical Center, Korea)
Scientific Symposium 9 (SS09)
Real-world challenges in GI oncology: Navigating complex treatment decisions
Date & Time Sep. 5 (Fri), 14:50-16:20 Venue Room C (Walker Hall 1)
Chair(s)
  • Ho Yeong Lim (CHA Bundang Medical Center, Korea)
  • Koji Kono (Fukushima Medical University, Japan)
Session Details
  1. 1. How can we adopt immunotherapy for MSS CRC?
    Hyun Jin Bang (Chonnam National University Hwasun Hospital, Korea)
  2. 2. Systemic treatment strategies for HCC with poor liver function
    Sadahisa Ogasawara (Chiba University, Japan)
  3. 3. Who benefits from neoadjuvant chemotherapy in resectable pancreatic cancer?
    Choong-kun Lee (Yonsei Cancer Center, Korea)
  4. 4. GI cancer with peritoneal metastasis: Hard-to-treat disease entity
    Raghav Sundar (Yale School of Medicine, USA)
Scientific Symposium 10 (SS10)
Revealing immune response and resistance through spatial profiling of NSCLC microenvironment
Date & Time Sep. 5 (Fri), 14:50-16:20 Venue Room D (Walker Hall 2)
Chair(s)
  • TBD
  • Chita I. Nazal-Matunog (San Pedro Hospital of Davao City, Philippines)
Session Details
  1. 1. Overview of tumor microenvironment of lung cancer
    Jaemoon Koh (Seoul National University Hospital, Korea)
  2. 2. AI-assisted TIL analysis as predictive biomarker for ICI in NSCLC
    Mehrdad Rakaee (Institute for Cancer Research, Oslo University Hospital, Norway)
  3. 3. Revealing immune response and resistance through spatial profiling of NSCLC
    Antoine Italiano (DITEP, Gustave Roussy, France)
  4. 4. Spatial interactomics: Mapping protein interplay to fight cancer
    Ece D. Gamsiz Uzun (The Warren Alpert Medical School of Brown University, USA)
Satellite Symposium 13 (SL13)
Redefining PI3K pathway inhibitors in HR+ breast cancer with Inavolisib
Date & Time Sep. 5 (Fri), 14:50-15:30 Venue Room E (Grand Hall 4)
Chair(s)
  • Kyung Hae Jung (Asan Medical Center, Korea)
Session Details
  1. Redefining PI3K pathway inhibitors in HR+ breast cancer with Inavolisib
    Seock-Ah Im (Seoul National University Hospital, Korea)
Satellite Symposium 14 (SL14)
Evolving management of mUC in Korea: Case-based insights and treatment strategies
Date & Time Sep. 5 (Fri), 15:40-16:20 Venue Room E (Grand Hall 4)
Chair(s)
  • Jae-Lyun Lee (Asan Medical Center, Korea)
Session Details
  1. 1. The evolution of mUC treatment in Korea: The significance of 1L maintenance
    In Ho Kim (The Catholic University of Korea Seoul St. Mary’s Hospital, Korea)
  2. 2. Treatment journey in mUC; Case-based learning
    Hongsik Kim (Chungbuk National University Hospital, Korea)